This website is owned and maintained by the Oncidium foundation, with support from Telix Pharmaceuticals. The NOBLE registry study is sponsored by the Principal Investigator and participating expert sites around the world. Telix provided funding support and drug to support the study purpose, but is not responsible for the design, output or results which are led and controlled by the independent team running the study. ^99mTc-iPSMA is authorised for investigational use only. None of the technologies described on the website have received a marketing authorisation in any jurisdiction.

Sources : www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/prostate-specific-antigen-psa-testing-prostate-cancer-screening – www.cancer.net/cancer-types/prostate-cancer/diagnosis – www.oncidiumfoundation.org/patient/prostate-cancer/ – www.ncbi.nlm.nih.gov/pmc/articles – www.snmmi.org/Patients/Procedures – www.radiopaedia.org/articles/spect-vs-pet – www.medraysintell.com/ – MEDRaysintell 2019 – Globocan: https://gco.iarc.fr/today

Search Results for: PEGACPBA23V1 Schulungsangebot, PEGACPBA23V1 Testing Engine, Certified Pega Business Architect 23 Trainingsunterlagen 🕦 Erhalten Sie den kostenlosen Download von [ PEGACPBA23V1 ] mühelos über ➠ www.itzert.com 🠰 🚔PEGACPBA23V1 Kostenlos Downloden

A first patient has been imaged in the NOBLE Registry Indonesia!

First Patient Imaged in NOBLE Registry Azerbaijan

First Patient Imaged in NOBLE Registry Mexico

First Patient Dosed in Rural Australia

Promising results in Egypt

Do you agree to continue ?